SEATTLE (April 20, 2016) Gen9 and Arzeda today announced an agreement for the supply of megabase quantities of synthetic DNA that will enable Arzeda to accelerate development of novel molecules for its own products as well as those of its partners. The collaboration is part of Gen9’s MAP program, designed to provide industrial users of synthetic DNA with access to game-changing economics for synthetic DNA.
SEATTLE and EMERYVILLE, Calif. (March 21, 2016) Zymergen and Arzeda announced today a multi-year agreement to develop strains and processes to manufacture novel, high utility molecules and materials utilizing Arzeda’s pathway and enzyme design and Zymergen’s strain construction capabilities.
Arzeda will help further develop Stratos’ “Sequencing by Design” technology for rapid single molecule DNA sequencing
SEATTLE, November 11, 2015 – Biotechnology company Arzeda announced today an Agreement with Stratos Genomics to assist development of novel enzymes supporting Stratos’ DNA sequencing technology.